Previous 10 | Next 10 |
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Precomplexing NK cells with Innate Cell Engagers (ICE ® molecules) results in a CAR-like NK cell product, whose magnitude and specificity of antibody-dependent cellular cytotoxicity (ADCC) remain unaffected after one freeze-thaw cycle Activity after cryopreservation is an...
HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following inv...
The mini-crash of January has given investors the opportunity to buy some amazing healthcare companies at a discount. First we're going to take a look at Doximity (NYSE: DOCS) , a telehealth powerhouse that is almost 60% off its highs. Next up is Novocure (NASDAQ: NVCR) , a ...
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022 FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose level, and (ii) treatment of patients with more than two cycles in the investigator ...
HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer Dr. Adi Hoess will present at the 40th Annual...
AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeys Pre-complexing AFM13 with NK cells generates CAR-like NK cells, which retain biological activity a...
For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient completed cycle 1 at the RP2D and was assessed with a partial response (PR) Three of 3 pat...
Affimed (NASDAQ:AFMD) has initiated patient recruitment for Phase 1/2a study evaluating the safety, tolerability, pharmacokinetics and efficacy of the innate cell engager (ICE) AFM24 in combination with Roche’s (OTCQX:RHHBY) atezolizumab. AFM24 is being developed for the treatment of p...
HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today the initiation of patient recruitment for the open-label, multi-center phase 1/...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...